Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity Hospital, Toulouse
About this trial
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Eligibility criteria
Qualifiers
Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
Admitted for right ventricle electrophysiologic mapping
For controls * Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.
Disqualifiers
Diagnostic of systemic chronic inflammatory disease
Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
Taking immunosuppressant or immunomodulating medications
Trial design
Treatments tested in this trial
- Peripheral immunological assessment on venous blood
- Immunological assessment carried out on intracardiac material
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov